Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

DCP Biorepositories

Biorepository for Prostate Cancer Prevention Trial (PCPT)

The PCPT biorepository and extended data was used to further explore the initial suggestion that some men taking finasteride were at risk of developing high-grade prostate cancers, and to look at the value of prostate-specific antigen (PSA) for early detection. Researchers showed that:

  • Finasteride improves the biopsy detection of prostate cancers (by reducing gland volume) and increases the sensitivity of PSA for detecting prostate cancer, in general, and high-grade cancer, in particular;
  • Men taking finasteride may not have increased risk of high-grade prostate cancer;
  • Finasteride prevents cancer for which treatment would be recommended;
  • Finasteride decreases risk of high-grade prostatic intraepithelial neoplasia (PIN), which may be a precursor to prostate cancer; and
  • Prostate cancer, including high-grade cancer, can be present even when PSA levels are 4.0 ng/ml or less.

An extensive investigator-initiated program project grant includes studies to evaluate androgen metabolism; diet and diet-related factors; insulin-like growth factor axis and insulin resistance; genotypic and phenotypic studies of inflammation; and oxidative damage and DNA repair.

or

The PCPT biorepository and extended data also was used in an extensive investigator-initiated program project grant that includes studies to evaluate androgen metabolism; diet and diet-related factors; insulin-like growth factor axis and insulin resistance; genotypic and phenotypic studies of inflammation; and oxidative damage and DNA repair.

References

Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep;99(18):1366-74. Epub 2007 Sep 11.
[ PubMed Abstract ]

Hoque A, Abrosone CB, Till C, et al. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2010 Apr;3(4):478-83. Epub2010 March 23.
[ PubMed Abstract ]

Kaplan SA, Roehrborn CG, Meehan AG, et al.: PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology. 2009 73(5):935-9. Epub 2009 Mar 28.
[ PubMed Abstract ]

Kristal AR, Schenk JM, Song Y, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 168 (12): 1416-24, 2008. Epub 2008 Oct 21.
[ PubMed Abstract ]

Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res. 2008 1(3):167-73. Epub 2008 May 18.
[ PubMed Abstract ]

Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.
[ PubMed Abstract ]

McKinney MM, Weiner BJ, Wang V. Recruiting participants to cancer prevention clinical trials: lessons from successful community oncology networks. Oncol Nurs Forum. 2006 Sep 1;33(5):951-9.
[ PubMed Abstract ]

Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res. 2008 1(3):182-6. Epub 2008 May 18.
[ PubMed Abstract ]

Price DK, Chau CH, Till C, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Urol. 2010 Dec:184(6):2297-302. Epub 2010 Oct 16.
[ PubMed Abstract ]

Redman M, Tangen C, Goodman P, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res. 2008 1 (3):174-81. Epub 2008 May 18
[ PubMed Abstract ]

Tang L, Yao S. Til C, et al. Repeat polymorphisms in estrogenmetabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogensis. 2011 Oct: 32 (10):1500-6. Epub 2011 Jul 18.
[ PubMed Abstract ]

Thompson IM, Ankerst DP, Chi C,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19;98(8):529-34.
[ PubMed Abstract ]

Thompson IM, Pauler Ankerst D, Chi C, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20;25(21):3076-81.
[ PubMed Abstract ]

Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004 May27; 350(22):2239-46.
[ PubMed Abstract ]

Yao S, Til C, Kristal AR, et al. Serum estrogen levels and prostate cancer risk in the Prostate Cancer Prevention Trial: a nested case-control study. Cancer Causes Control. 2011 Aug:22(8):1121-31. Epub 2011 Jun 11.
[ PubMed Abstract ]


Back to top